Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Barakat

Showing results (211-220 of 402) with videos related to

Pageof 41
Sort By:
Gynecologic Oncology|May 1, 1993
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatmentM Markman, T Hakes, B Reichman, et al.
Cancer|February 15, 1993
Intraperitoneal chemotherapy in the management of ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicityP Francis, M Markman, T Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide coursesD Fennelly, J Schneider, D Spriggs, et al.
Gynecologic Oncology|December 11, 1992
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancerM Markman, B Reichman, T Hakes, et al.
American Journal of Obstetrics and Gynecology|May 20, 2005
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancersDennis S Chi, Nadeem R Abu-Rustum, Yukio Sonoda, et al.
Gynecologic Oncology|December 8, 2004
A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?Yukio Sonoda, Nadeem R Abu-Rustum, Mary L Gemignani, et al.
Gynecologic Oncology|September 24, 2013
Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapyNeil B Desai, Ana P Kiess, Marisa A Kollmeier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Seminars in Oncology|December 11, 1992
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?M Markman, T Hakes, B Reichman, et al.
Pageof 41

Showing results (211-220 of 402) with videos related to

Sort By:
Pageof 41
Gynecologic Oncology|May 1, 1993
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatmentM Markman, T Hakes, B Reichman, et al.
Cancer|February 15, 1993
Intraperitoneal chemotherapy in the management of ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicityP Francis, M Markman, T Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide coursesD Fennelly, J Schneider, D Spriggs, et al.
Gynecologic Oncology|December 11, 1992
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancerM Markman, B Reichman, T Hakes, et al.
American Journal of Obstetrics and Gynecology|May 20, 2005
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancersDennis S Chi, Nadeem R Abu-Rustum, Yukio Sonoda, et al.
Gynecologic Oncology|December 8, 2004
A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?Yukio Sonoda, Nadeem R Abu-Rustum, Mary L Gemignani, et al.
Gynecologic Oncology|September 24, 2013
Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapyNeil B Desai, Ana P Kiess, Marisa A Kollmeier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Seminars in Oncology|December 11, 1992
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?M Markman, T Hakes, B Reichman, et al.
Pageof 41